The table below shows Regencell Bioscience Holdings Ltd's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$3.11M
-$4.00M
-$4.96M
-$5.27M
-$767.31K
-$726.57K
Capital expenditure
$152.69K
$5.38K
$27.39K
$780.88K
-
$117.84K
Investing cash flow
$2.69M
$5.24M
$58.98K
-$10.78M
-
-$117.84K
Dividends paid
-
-
-
-
-
RGC operating cash flow (10-K history)
Regencell Bioscience Holdings Ltd reported operating cash flow of -$3.11M for fiscal year 2025. That is up 22.2% from -$4.00M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$390.99K (FY 2019) to -$3.11M. Figures come from the company's audited annual reports as filed with the SEC.
